https://pharmatimes.com/news/
https://pharmatimes.com/news/cancer-grand-challenges-launches-global-initiative-to-tackle-cancers-toughest-problems/
https://pharmatimes.com/news/cancer-grand-challenges-launches-global-initiative-to-tackle-cancers-toughest-problems/
https://pharmatimes.com/news/algotx-completes-pivotal-phase-2-trial-for-ground-breaking-cipn-treatment/
https://pharmatimes.com/news/algotx-completes-pivotal-phase-2-trial-for-ground-breaking-cipn-treatment/
https://pharmatimes.com/news/oncologica-to-advance-urine-based-prostate-cancer-screening-test/
https://pharmatimes.com/news/oncologica-to-advance-urine-based-prostate-cancer-screening-test/
https://pharmatimes.com/news/leeds-teaching-hospitals-nhs-trust-evaluates-ai-software-for-prostate-cancer-diagnosis/
https://pharmatimes.com/news/leeds-teaching-hospitals-nhs-trust-evaluates-ai-software-for-prostate-cancer-diagnosis/
https://pharmatimes.com/news/flypharma-europe-vienna-october-2024-conference/
https://pharmatimes.com/news/flypharma-europe-vienna-october-2024-conference/
https://pharmatimes.com/news/ukris-mrc-awards-27-4m-to-university-of-dundee-research-unit/
https://pharmatimes.com/news/ukris-mrc-awards-27-4m-to-university-of-dundee-research-unit/
https://pharmatimes.com/news/who-adds-first-mpox-vaccine-to-prequalification-list/
https://pharmatimes.com/news/who-adds-first-mpox-vaccine-to-prequalification-list/
https://pharmatimes.com/news/world-sepsis-day-2024-highlights-need-for-better-sepsis-treatments/
https://pharmatimes.com/news/world-sepsis-day-2024-highlights-need-for-better-sepsis-treatments/
https://pharmatimes.com/news/nxera-and-cancer-research-uk-to-present-promising-cancer-drug-trial-at-esmo/
https://pharmatimes.com/news/nxera-and-cancer-research-uk-to-present-promising-cancer-drug-trial-at-esmo/
https://pharmatimes.com/news/hrt-linked-to-reduced-psychosis-relapse-risk-in-menopausal-women/
https://pharmatimes.com/news/hrt-linked-to-reduced-psychosis-relapse-risk-in-menopausal-women/
https://pharmatimes.com/news/centessa-reports-positive-phase-1-clinical-data-for-orx750/
https://pharmatimes.com/news/centessa-reports-positive-phase-1-clinical-data-for-orx750/
https://pharmatimes.com/news/scotland-first-in-uk-to-approve-new-myeloma-treatment/
https://pharmatimes.com/news/scotland-first-in-uk-to-approve-new-myeloma-treatment/
https://pharmatimes.com/news/ai-powered-chest-x-rays-detect-lung-cancer-early/
https://pharmatimes.com/news/ai-powered-chest-x-rays-detect-lung-cancer-early/
https://pharmatimes.com/news/phase-2-predict-ild-imaging-study-commences-in-interstitial-lung-disease/
https://pharmatimes.com/news/phase-2-predict-ild-imaging-study-commences-in-interstitial-lung-disease/
https://pharmatimes.com/news/apl-and-curifylabs-partner-to-support-patients-with-3d-printing-medicine-technology/
https://pharmatimes.com/news/apl-and-curifylabs-partner-to-support-patients-with-3d-printing-medicine-technology/
https://pharmatimes.com/news/page/2/?et_blog
https://pharmatimes.com/news/
